Under the collaboration, GNS will use its supercomputer-driven Reverse Engineering and Forward Simulation (REFS) platform, while Covance will utilize its data assets derived from its extensive clinical and scientific support of pharmaceutical drug development.
The companies will use computer models to assess the drug’s safety and efficacy across a variety of patient characteristics as well as across many diseases including type II Diabetes.
The terms of GNS Healthcare’s deal with Covance have not been disclosed.
GNS Healthcare president, CEO and co-founder Colin Hill said the predictive computer models are being developed to improve dismal clinical drug development success rates.
"The predictive computer models arising from our collaboration will address this problem and will in turn lead to better treatment options for patients," Hill added.
"The collaboration with Covance is a key part of our expanding portfolio of relationships with customers and partners employing the REFS platform to learn what drugs work for whom in healthcare."